Displaying 25 - 34 of 34
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Displaying 25 - 34 of 34